Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 9/1/09 → 8/31/11 |
Funding
- Novo Nordisk Pharmaceuticals Inc: $122,469.00
A 52 Week Randomized, Controlled, Open Label, Multicenter, Multinational, Parallel, Treat to Target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily
- Karounos, Dennis (PI)